PT - JOURNAL ARTICLE AU - Yao-Chung Liu AU - Emiliano Fabiani AU - Junsu Kwon AU - Chong Gao AU - Giulia Falconi AU - Lia Valentini AU - Carmelo Gurnari AU - Yanjing V. Liu AU - Adrianna I. Jones AU - Junyu Yang AU - Henry Yang AU - Julie A. I. Thoms AU - Ashwin Unnikrishnan AU - John E. Pimanda AU - Rongqing Pan AU - Maria Teresa Voso AU - Daniel G. Tenen AU - Li Chai TI - Demethylation and upregulation of an oncogene post hypomethylating treatment AID - 10.1101/2020.07.21.20157776 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.21.20157776 4099 - http://medrxiv.org/content/early/2020/09/07/2020.07.21.20157776.short 4100 - http://medrxiv.org/content/early/2020/09/07/2020.07.21.20157776.full AB - Background While hypomethylating agents (HMA) are currently used to treat myelodysplastic syndrome (MDS) patients, their effects on reactivation and/or upregulation of oncogenes are generally not well elucidated. SALL4 is a known oncogene that plays an important role in MDS. In this study, we examined the relationship between SALL4 methylation and expression, and evaluated changes of SALL4 expression and their prognostic value in MDS patients undergoing HMA treatment.Methods No/low-SALL4 expressing leukemic K562 and HL-60 cell lines were used to study the relationship between SALL4 methylation and expression. Additionally, paired bone marrow (BM) samples from MDS patients on the BMT-AZA trial (EudraCT number 2010-019673-15), collected before and after four cycles of azacytidine (AZA) treatment, were used to explore the relationship between changes in SALL4 expression, treatment response and clinical outcome.Findings In cell lines, we identified that demethylation of a critical CpG region was associated with increased SALL4 expression, and HMA treatment led to demethylation of this region and upregulation of SALL4. In MDS patients, we noted SALL4 upregulation after four cycles of AZA treatment in 40% of the cases. Significantly, patients in the responder group with SALL4 upregulation had the worst outcome.Interpretation This is the first study on demethylation and upregulation of the SALL4 oncogene after HMA treatment in MDS patients, and its clinical impact on treatment response and outcome. Our data indicate that MDS patients receiving HMA treatment should be monitored for SALL4 upregulation for poor outcome, especially in HMA responders.Funding Myeloid Neoplasms Research Venture AIRC MYNERVA, National Institutes of Health; Singapore Ministry of Health’s National Medical Research Council; Leukemia and Lymphoma Society and Xiu Research Fund.Evidence before this study We searched PubMed on May 9, 2020, with no starting date limitations, using the search terms “hypomethylating agent”, “prognosis”, “myelodysplastic syndrome”, “oncogene” and “demethylation”. Our literature search did not show any report on oncogene demethylation and/or re-activation as a result of hypomethylating agent (HMA) treatment for myelodysplastic syndrome (MDS). While HMAs are currently used to treat MDS patients, their effects on reactivation and/or upregulation of oncogenes are generally not well elucidated. In addition, the survival after HMA in ‘real-world’ high risk (HR)-MDS/low-blast count acute myeloid leukemia (AML) was lower than the expected overall survival (OS) in clinical trials, and the outcome after HMA failure was less than 6 months. To date, there is no treatment available to improve OS after HMA failure.Added value of this study SALL4 is a known oncogene that plays an important role in MDS. In this study, we examined the relationship between SALL4 methylation and expression, and evaluated changes of SALL4 expression and their prognostic value in MDS patients undergoing HMA treatment. No/low-SALL4 expressing leukemic K562 and HL-60 cell lines were used to study the relationship between SALL4 methylation and expression. Additionally, paired bone marrow (BM) samples from MDS patients on the BMT-AZA trial (EudraCT number 2010-019673-15), collected before and after four cycles of azacytidine (AZA) treatment, were used to explore the relationship between changes in SALL4 expression, treatment response and clinical outcome.Implications of all the available evidence In cell lines, we identified that demethylation of a critical CpG region was associated with increased SALL4 expression, and HMA treatment led to demethylation of this region and upregulation of SALL4. In MDS patients, we noted SALL4 upregulation after four cycles of AZA treatment in 40% of the cases. Significantly, patients in the responder group with SALL4 upregulation had the worst outcome. Our data indicate that MDS patients receiving HMA treatment should be monitored for SALL4 upregulation for poor outcome, especially in HMA responders.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialEudraCT number 2010-019673-15Funding StatementThis study was supported by Myeloid Neoplasms Research Venture AIRC MYNERVA, National Institutes of Health; Singapore Ministry of Health's National Medical Research Council; Leukemia and Lymphoma Society and Xiu Research FundAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:BM samples were obtained from 37 newly diagnosed MDS patients enrolled in the BMT-AZA trial (EudraCT number 2010-019673-15). The study was approved by the IRB at University of Roma Tor VergataAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data in the main manuscript and supplementary data are available on request